Phathom Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsPhathom Pharmaceuticals

Phathom Pharmaceuticals(PHAT)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Voquezna dual	Amoxicillin, Vonoprazan	2022-05-03	2026-2042	Urinary tract infections , Sinusitis , Otitis media , Bacterial infections , Bacterial skin diseases , Soft tissue infections , Chlamydia infections , Helicobacter infections , Duodenal ulcer , Streptococcal infections , Lyme disease , Listeriosis , Human bites , Actinomycosis , Staphylococcal infections , Haemophilus infections , Nontuberculous mycobacterium infections , Gastroesophageal reflux , Infectious skin diseases , Mycoplasma pneumonia , Bronchitis , Stomach ulcer , Tonsillitis , Zollinger-ellison syndrome , Esophagitis , Protozoan infections , Pulmonary tuberculosis , Mycobacterium avium-intracellulare infection , Heartburn , Mycobacterium infections
Voquezna triple	Amoxicillin, Clarithromycin, Vonoprazan	2022-05-03	2026-2042	Urinary tract infections , Sinusitis , Otitis media , Bacterial infections , Bacterial skin diseases , Soft tissue infections , Chlamydia infections , Helicobacter infections , Duodenal ulcer , Streptococcal infections , Lyme disease , Listeriosis , Human bites , Actinomycosis , Staphylococcal infections , Haemophilus infections , Nontuberculous mycobacterium infections , Gastroesophageal reflux , Infectious skin diseases , Mycoplasma pneumonia , Bronchitis , Stomach ulcer , Tonsillitis , Zollinger-ellison syndrome , Esophagitis , Protozoan infections , Pulmonary tuberculosis , Mycobacterium avium-intracellulare infection , Heartburn , Mycobacterium infections
Voquezna	Vonoprazan	2023-11-01	2028-2030	Urinary tract infections , Sinusitis , Otitis media , Bacterial infections , Bacterial skin diseases , Soft tissue infections , Chlamydia infections , Helicobacter infections , Duodenal ulcer , Streptococcal infections , Lyme disease , Listeriosis , Human bites , Actinomycosis , Nontuberculous mycobacterium infections , Infectious skin diseases , Mycoplasma pneumonia , Bronchitis , Tonsillitis , Staphylococcal infections , Haemophilus infections , Protozoan infections

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

communicable diseases

,

helicobacter infections

,

communicable diseases

,

helicobacter infections

healthy volunteers/patients

,

peptic esophagitis

,

gastroesophageal reflux

,

,

,

,

communicable diseases

,

helicobacter infections

gastroesophageal reflux

,

,

communicable diseases

,

helicobacter infections

,

communicable diseases

,

helicobacter infections

healthy volunteers/patients

,

,

communicable diseases

,

helicobacter infections

,

gastroesophageal reflux

,

© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use